Sinovac Biotech Ltd (SVA) - Total Liabilities
Based on the latest financial reports, Sinovac Biotech Ltd (SVA) has total liabilities worth $1.67 Billion USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore SVA long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Sinovac Biotech Ltd - Total Liabilities Trend (1998–2025)
This chart illustrates how Sinovac Biotech Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Sinovac Biotech Ltd assets under control.
Sinovac Biotech Ltd Competitors by Total Liabilities
The table below lists competitors of Sinovac Biotech Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Papa John's International Inc
NASDAQ:PZZA
|
USA | $1.25 Billion |
|
Baotou Huazi Industry Co Ltd
SHG:600191
|
China | CN¥563.98 Million |
|
Guangdong Insight Brand Marketing Group Co Ltd
SHE:300781
|
China | CN¥246.46 Million |
|
Nanjing Quanxin Cable Technology Co Ltd
SHE:300447
|
China | CN¥437.87 Million |
|
New York Mortgage Trust Inc
NASDAQ:NYMT
|
USA | $9.16 Billion |
|
Basellandschaftliche Kantonalbank
SW:BLKB
|
Switzerland | CHF32.88 Billion |
|
Xinjiang Yilite Industry Co Ltd
SHG:600197
|
China | CN¥1.94 Billion |
|
Mingchen Health Co Ltd Class A
SHE:002919
|
China | CN¥440.15 Million |
Liability Composition Analysis (1998–2025)
This chart breaks down Sinovac Biotech Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See SVA net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sinovac Biotech Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sinovac Biotech Ltd (1998–2025)
The table below shows the annual total liabilities of Sinovac Biotech Ltd from 1998 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.23 Billion | +9.27% |
| 2024-12-31 | $2.04 Billion | +24.99% |
| 2023-12-31 | $1.64 Billion | +16.64% |
| 2022-12-31 | $1.40 Billion | -51.19% |
| 2021-12-31 | $2.87 Billion | +267.66% |
| 2020-12-31 | $781.20 Million | +680.39% |
| 2019-12-31 | $100.10 Million | +28.58% |
| 2018-12-31 | $77.85 Million | -4.70% |
| 2017-12-31 | $81.69 Million | 0.00% |
| 2016-12-31 | $81.69 Million | +22.98% |
| 2015-12-31 | $66.42 Million | -31.39% |
| 2014-12-31 | $96.80 Million | -0.26% |
| 2013-12-31 | $97.05 Million | +22.35% |
| 2012-12-31 | $79.33 Million | +12.35% |
| 2011-12-31 | $70.61 Million | +6.02% |
| 2010-12-31 | $66.60 Million | +9.16% |
| 2009-12-31 | $61.01 Million | +156.32% |
| 2008-12-31 | $23.80 Million | -3.03% |
| 2007-12-31 | $24.55 Million | +56.33% |
| 2006-12-31 | $15.70 Million | +128.94% |
| 2005-12-31 | $6.86 Million | 0.00% |
| 2004-12-31 | $6.86 Million | +71.01% |
| 2003-12-31 | $4.01 Million | +2831.33% |
| 2002-12-31 | $136.81K | -85.63% |
| 2001-12-31 | $952.15K | 0.00% |
| 2000-12-31 | $952.15K | +21058.89% |
| 1998-12-31 | $4.50K | -- |
About Sinovac Biotech Ltd
Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza;… Read more